200 related articles for article (PubMed ID: 16603433)
1. The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population.
Tsujino T; Ohara N; Yoshida S; Kennedy S; Takemura N; Deguchi M; Maruo T
Gynecol Endocrinol; 2006 Feb; 22(2):87-91. PubMed ID: 16603433
[TBL] [Abstract][Full Text] [Related]
2. Association of the CYP17 gene polymorphism with risk for uterine leiomyoma in Brazilian women.
Vieira LC; Gomes MT; Castro Rde A; de Souza NC; da Silva ID; Baracat EC; Girão MJ
Gynecol Endocrinol; 2008 Jul; 24(7):373-7. PubMed ID: 18645709
[TBL] [Abstract][Full Text] [Related]
3. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
5. A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study.
Amant F; Dorfling CM; de Brabanter J; Vandewalle J; Vergote I; Lindeque BG; van Rensburg EJ
Acta Obstet Gynecol Scand; 2004 Mar; 83(3):234-9. PubMed ID: 14995917
[TBL] [Abstract][Full Text] [Related]
6. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between CYP17 Mspa1 polymorphism and prostate cancer risk: a meta-analysis of 14494 cases and 15971 controls.
Song G; Gu L; Tian F; Bao Q; Tang Z; Wang S
Medicina (Kaunas); 2013; 49(2):51-5. PubMed ID: 23888338
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.
Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R
Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-1 and -9 promoter polymorphisms are not associated with an increased risk of uterine leiomyomas in a Japanese population.
Takemura N; Yoshida S; Kennedy S; Deguchi M; Ohara N; Maruo T
J Soc Gynecol Investig; 2006 Apr; 13(3):232-6. PubMed ID: 16638593
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma.
Denschlag D; Bettendorf H; Watermann D; Keck C; Tempfer C; Pietrowski D
Fertil Steril; 2005 Jul; 84(1):162-6. PubMed ID: 16009172
[TBL] [Abstract][Full Text] [Related]
11. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
12. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Chakraborty A; Murthy NS; Chintamani C; Bhatnagar D; Mohil RS; Sharma PC; Saxena S
J Hum Genet; 2007; 52(2):159-165. PubMed ID: 17235448
[TBL] [Abstract][Full Text] [Related]
13. The CYP17 MspA1 Polymorphism and the Gender Dysphoria.
Fernández R; Cortés-Cortés J; Esteva I; Gómez-Gil E; Almaraz MC; Lema E; Rumbo T; Haro-Mora JJ; Roda E; Guillamón A; Pásaro E
J Sex Med; 2015 Jun; 12(6):1329-33. PubMed ID: 25929975
[TBL] [Abstract][Full Text] [Related]
14. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas.
Rosa FE; Canevari Rde A; Ambrosio EP; Ramos Cirilo PD; Pontes A; Rainho CA; Rogatto SR
Clin Chem Lab Med; 2008; 46(6):814-23. PubMed ID: 18601603
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.
Mao C; Wang XW; He BF; Qiu LX; Liao RY; Luo RC; Chen Q
Breast Cancer Res Treat; 2010 Jul; 122(1):259-65. PubMed ID: 20033766
[TBL] [Abstract][Full Text] [Related]
17. Association study between catechol-O-methyltransferase polymorphisms and uterine leiomyomas in a Japanese population.
Morikawa J; Yoshida S; Kennedy S; Takemura N; Sugimoto M; Kitao K; Deguchi M; Ohara N; Maruo T
Clin Exp Obstet Gynecol; 2008; 35(1):35-40. PubMed ID: 18390078
[TBL] [Abstract][Full Text] [Related]
18. Uterine leiomyoma is associated with a polymorphism in the interleukin 1-beta gene.
Pietrowski D; Thewes R; Sator M; Denschlag D; Keck C; Tempfer C
Am J Reprod Immunol; 2009 Aug; 62(2):112-7. PubMed ID: 19614627
[TBL] [Abstract][Full Text] [Related]
19. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Hou L; Xu J; Gao YT; Rashid A; Zheng SL; Sakoda LC; Shen MC; Wang BS; Deng J; Han TQ; Zhang BH; Meyers DA; Fraumeni JF; Hsing AW
Int J Cancer; 2006 Jun; 118(11):2847-53. PubMed ID: 16381022
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D
Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
